Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Hartsdale, NY
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Hartsdale, NY
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Rochester, NY
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Raleigh, NC
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Winston Salem, NC
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Toledo, OH
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Altoona, PA
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Altoona, PA
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Johnstown, PA
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Johnstown, PA
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Austin, TX
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Clinical Research Facility
mi
from
Seattle, WA
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated:  1/28/2016
Investigational Site Number 203002
mi
from
Olomouc,
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Multinational, Multicenter, Randomized Double-Blind, Placebo-Controlled, Parallel-Group Study of Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Status: Enrolling
Updated: 1/28/2016
Investigational Site Number 203002
mi
from
Olomouc,
Click here to add this to my saved trials
Central Auditory Processing Deficits Associated With Blast Exposure
Central Auditory Processing Deficits Associated With Blast Exposure
Status: Enrolling
Updated:  1/28/2016
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Central Auditory Processing Deficits Associated With Blast Exposure
Central Auditory Processing Deficits Associated With Blast Exposure
Status: Enrolling
Updated: 1/28/2016
VA Portland Health Care System, Portland, OR
mi
from
Portland, OR
Click here to add this to my saved trials
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated:  1/28/2016
University of Iowa
mi
from
Iowa City, IA
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated: 1/28/2016
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated:  1/28/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated: 1/28/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated:  1/28/2016
Moses Cone
mi
from
Greensboro, NC
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated: 1/28/2016
Moses Cone
mi
from
Greensboro, NC
Click here to add this to my saved trials
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated:  1/28/2016
Saint Thomas Hospital
mi
from
Nashville, TN
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated: 1/28/2016
Saint Thomas Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated:  1/28/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
The MIND Study: Modifying the INcidence of Delirium
Delirium in the ICU: a Prospective, Randomized, Trial of Placebo vs. Haloperidol vs. Ziprasidone
Status: Enrolling
Updated: 1/28/2016
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/28/2016
Sanofi-Aventis Administrave Office
mi
from
Bridgewater, NJ
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/28/2016
Sanofi-Aventis Administrave Office
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated:  1/28/2016
Sanofi-Aventis Administrative Office
mi
from
Bridgewater, NJ
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated: 1/28/2016
Sanofi-Aventis Administrative Office
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated:  1/28/2016
Sanofi-aventis Administrative Office
mi
from
Laval,
Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients With Multiple Sclerosis.
Status: Enrolling
Updated: 1/28/2016
Sanofi-aventis Administrative Office
mi
from
Laval,
Click here to add this to my saved trials
JC Virus Reactivation in Multiple Sclerosis
JC Virus Reactivation in Multiple Sclerosis
Status: Enrolling
Updated:  1/28/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
JC Virus Reactivation in Multiple Sclerosis
JC Virus Reactivation in Multiple Sclerosis
Status: Enrolling
Updated: 1/28/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Telehealth-Based Exercise Program to Treat Fatigue in MS
Telehealth-Based Exercise Program to Treat Fatigue in MS
Status: Enrolling
Updated:  1/29/2016
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
Telehealth-Based Exercise Program to Treat Fatigue in MS
Telehealth-Based Exercise Program to Treat Fatigue in MS
Status: Enrolling
Updated: 1/29/2016
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
Status: Enrolling
Updated:  1/29/2016
UC Davis Medical Center, Clinical Research Center
mi
from
Sacramento, CA
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
A Pre-Cellular Therapy Observational Study in Early Huntington's Disease
Status: Enrolling
Updated: 1/29/2016
UC Davis Medical Center, Clinical Research Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
Status: Enrolling
Updated:  1/30/2016
Clinical Research Facility
mi
from
Overland Park, KA
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
Status: Enrolling
Updated: 1/30/2016
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
Status: Enrolling
Updated:  1/30/2016
mi
from
Montreal,
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
Status: Enrolling
Updated: 1/30/2016
mi
from
Montreal,
Click here to add this to my saved trials
Evaluation of Robot Assisted Neuro-Rehabilitation
Evaluation of Robot Assisted Neuro-rehabilitation
Status: Enrolling
Updated:  2/1/2016
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Evaluation of Robot Assisted Neuro-Rehabilitation
Evaluation of Robot Assisted Neuro-rehabilitation
Status: Enrolling
Updated: 2/1/2016
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
mi
from
Baltimore, MD
Click here to add this to my saved trials
Parenting Your Young Child With Autism: A Web-Based Tutorial
Parenting Your Young Child With Autism: A Web-Based Tutorial
Status: Enrolling
Updated:  2/1/2016
Center for Psychological Consulation
mi
from
Madison, WI
Parenting Your Young Child With Autism: A Web-Based Tutorial
Parenting Your Young Child With Autism: A Web-Based Tutorial
Status: Enrolling
Updated: 2/1/2016
Center for Psychological Consulation
mi
from
Madison, WI
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
University of California - Irvine Medical Center
mi
from
Irvine, CA
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
University of California - Irvine Medical Center
mi
from
Irvine, CA
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
Rady Children's Hospital
mi
from
San Diego, CA
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
University of Florida College of Medicine
mi
from
Gainesville, FL
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
University of Florida College of Medicine
mi
from
Gainesville, FL
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
Kansas University Medical Center
mi
from
Kansas City, KA
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
Children's Hospital Boston
mi
from
Boston, MA
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
Greenwood Genetic Center
mi
from
Greenwood, SC
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
Greenwood Genetic Center
mi
from
Greenwood, SC
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
Vanderbilt University
mi
from
Nashville, TN
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated:  2/1/2016
Baylor College of Medicine
mi
from
Houston, TX
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi
Status: Enrolling
Updated: 2/1/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Autologous Cell Therapy After Stroke
Safety of IV Autologous Mononuclear Cells and Marrow Stromal Cells After Stroke
Status: Enrolling
Updated:  2/2/2016
Uc Irvine Medical Center
mi
from
Orange, CA
Autologous Cell Therapy After Stroke
Safety of IV Autologous Mononuclear Cells and Marrow Stromal Cells After Stroke
Status: Enrolling
Updated: 2/2/2016
Uc Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Influence of Timing on Motor Learning
Influence of Timing on Motor Learning
Status: Enrolling
Updated:  2/2/2016
University of California, Irvine
mi
from
Irvine, CA
Influence of Timing on Motor Learning
Influence of Timing on Motor Learning
Status: Enrolling
Updated: 2/2/2016
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Decision Aids in Cerebral Aneurysm Treatment
Decision Aids in Cerebral Aneurysm Treatment
Status: Enrolling
Updated:  2/2/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Decision Aids in Cerebral Aneurysm Treatment
Decision Aids in Cerebral Aneurysm Treatment
Status: Enrolling
Updated: 2/2/2016
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Orthotics in Ambulatory Cerebral Palsy
Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy
Status: Enrolling
Updated:  2/3/2016
Seattle Children'S Research Institute
mi
from
Seattle, WA
Orthotics in Ambulatory Cerebral Palsy
Relationship of Orthotics to Activity and Participation in Children With Cerebral Palsy
Status: Enrolling
Updated: 2/3/2016
Seattle Children'S Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome
Status: Enrolling
Updated:  2/3/2016
Teva Investigational Site
mi
from
Houston, TX
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)
A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome
Status: Enrolling
Updated: 2/3/2016
Teva Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Birmingham, AL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Aventura, FL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Aventura, FL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Decatur, IL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Decatur, IL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Indianapolis, IN
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Ashland, KY
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Ashland, KY
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Concord, MA
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Concord, MA
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
St Clair Shores, MI
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
St Clair Shores, MI
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Tupelo, MS
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Tupelo, MS
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Great Falls, MT
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Great Falls, MT
Click here to add this to my saved trials